Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Latest Information Update: 20 Apr 2023
Price :
$35 *
At a glance
- Drugs Mevidalen (Primary)
- Indications Dementia; Lewy body disease; Parkinson's disease
- Focus Therapeutic Use
- Acronyms PRESENCE
- Sponsors Eli Lilly and Company
- 01 Apr 2023 Results assessing whether digital measures from patients with mild-to-moderate Lewy Body Dementia demonstrate treatment effects during a randomized Phase 2 trial published in the Parkinsonism and Related Disorders
- 18 Sep 2022 Results evaluating if wrist actigraphy data can derive clinically meaningful information reflecting circadian rhythm and motor functions from patients with Lewy body dementiapresented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 02 Dec 2021 Results published in the Movement Disorders